JG
OREX

Jefferies Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Jefferies Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-5,000
Closed -$292K – 2467
2013
Q2 		$292K Buy
+5,000
New +$308K ﹤0.01% 1329

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jefferies Group's OREX Position: Q2 2017 in Review

Jefferies Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2017, closing a stake of 25,000 shares — an estimated $86K sold.

Jefferies Group first reported a position in OREX in Q2 2013 and held it in 5 quarters. The position peaked at $211K in Q1 2014. 51 funds tracked by Wall St. Rank hold OREX as of Q2 2017.

  • Jefferies Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Jefferies Group sold 25,000 Orexigen Therapeutics, Inc. shares in Q2 2017, an estimated $86K.
  • Jefferies Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
  • Jefferies Group's Orexigen Therapeutics, Inc. position peaked at $211K in Q1 2014.
  • 51 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2017.

Based on Jefferies Group's 13F filing for Q2 2017, filed 14 Aug 2017.